Trial Profile
A multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and clinical efficacy of intravenous infusions of BMS-188667 [abatacept] (10 mg/kg) given monthly in combination with subcutaneous injections of etanercept (25 mg) given twice weekly to subjects with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Etanercept
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 02 Nov 2006 Status change
- 10 Feb 2006 New trial record.